On Tuesday,Intra-Cellular Therapies, Inc.(NASDAQ:ITCI) reported results from Study 304 of lumateperone 42 mg for the prevention of relapse in adult patients with schizophrenia.
On the primary endpoint, the time to relapse during the double-blind treatment phase was significantly longer in patients receiving lumateperone than in those receiving placebo (p=0.0002).
There were 18 relapses (16.4%) in the lumateperone group versus 44 relapses (38.6%) in the placebo group.
Also Read: Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo.
Lumateperone also met the key secondary endpoint, time...
ログインすると全部閲覧できます。
ログイン